We are live on ! Find out more
DMRA

Damora Therapeutics, Inc. Ordinary Shares
DMRA

26 hedge funds and large institutions have $9.59M invested in Damora Therapeutics, Inc. Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

13% more funds holding

Funds holding: 23 → 26 (+3)

11% more capital invested

Capital invested by funds: $8.68M → $9.59M (+$918K)

0% more ownership

Funds ownership: 1.44% → 1.44% (+0%)

20% less call options, than puts

Call options by funds: $56K | Put options by funds: $70K

Holders
26
Holders Change
+3
Holders Change %
+13.04%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
4
Closed
1
Calls
$56K
Puts
$70K
Net Calls
-$14K
Net Calls Change
-$14K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$107K
2
FIA
FNY Investment Advisers
New York
+$85.2K
3
Federated Hermes
Federated Hermes
Pennsylvania
+$40.6K
4
MCM
MAI Capital Management
Ohio
+$36.7K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$20.6K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$137K
2
Two Sigma Investments
Two Sigma Investments
New York
-$34K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$26.2K
4
Millennium Management
Millennium Management
New York
-$23.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$4.72M – – –
CAM
2
Cormorant Asset Management
Massachusetts
$1.93M – – –
MCM
3
MAI Capital Management
Ohio
$641K +$36.7K +723 +6%
LCM
4
Laurion Capital Management
New York
$360K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$339K -$137K -2,696 -27%
BCM
6
Bridgeway Capital Management
Texas
$327K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$200K – – –
Two Sigma Advisers
8
Two Sigma Advisers
New York
$174K -$26.2K -516 -12%
MAM
9
Marquette Asset Management
Minnesota
$114K – – –
Federated Hermes
10
Federated Hermes
Pennsylvania
$113K +$40.6K +800 +50%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$99K +$107K +2,109 New
Bank of America
12
Bank of America
North Carolina
$89K +$20K +394 +27%
Two Sigma Investments
13
Two Sigma Investments
New York
$88K -$34K -670 -26%
State Street
14
State Street
Massachusetts
$85K – – –
FIA
15
FNY Investment Advisers
New York
$79K +$85.2K +1,680 New
Vanguard Group
16
Vanguard Group
Pennsylvania
$65K – – –
Northern Trust
17
Northern Trust
Illinois
$39K – – –
Millennium Management
18
Millennium Management
New York
$36K -$23.4K -462 -38%
BlackRock
19
BlackRock
New York
$31K +$5.02K +99 +17%
Commonwealth Equity Services
20
Commonwealth Equity Services
Massachusetts
$19K +$20.6K +407 New
Simplex Trading
21
Simplex Trading
Illinois
$18K +$18.5K +365 +1,921%
UBS Group
22
UBS Group
Switzerland
$8K +$8.32K +164 New
O
23
OrbiMed
New York
$7.73K – – –
TRCT
24
Tower Research Capital (TRC)
New York
$6K +$862 +17 +16%
Wells Fargo
25
Wells Fargo
California
$5K +$51 +1 +0.8%
1
2

DMRA Hedge Fund Activity: Q3 2022 in Review

26 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q3 2022, worth a combined $9.59M — up 11% from $8.68M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new DMRA positions and 1 closed out — a net gain of 3 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $107K. The largest seller was Renaissance Technologies, cutting an estimated $137K.

  • 26 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q3 2022, up from 23 in Q2 2022.
  • Funds reported $9.59M of Damora Therapeutics, Inc. Ordinary Shares stock for Q3 2022, up 11% quarter-over-quarter.
  • 4 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q3 2022 and 1 closed out, a net change of +3 holders.
  • The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q3 2022 was Susquehanna International Group, an estimated $107K added.
  • The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q3 2022 was Renaissance Technologies, an estimated $137K sold.

Based on aggregated 13F filings for Q3 2022.